Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 21 January 2026 - 1 February 2026

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

The Health Care Select Sector SPDR Fund (XLV) rose 0.6% to $154.74 Friday, while the S&P 500 fell 0.43%. Healthcare and consumer staples were the only S&P sectors in positive territory as investors shifted to defensive stocks. Major managed-care shares lagged after a minimal proposed Medicare Advantage rate hike. Pfizer, Merck, and Eli Lilly report earnings next week.
1 February 2026
········
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
··········
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
·······
Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer shares fell 1.7% to $26.06 after CMS selected its arthritis drug Xeljanz for Medicare price negotiations, with new prices set for 2028. Xeljanz accounted for about $1.01 billion in Medicare spending in the latest period. Investors await Pfizer’s Feb. 3 quarterly results and a Feb. 28 CMS deadline for drugmakers to sign participation agreements.
28 January 2026
····
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
········
Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision

Pfizer shares rose 0.7% to $25.84 in Monday afternoon trading, tracking a broader U.S. stock rally ahead of major earnings and a Federal Reserve policy decision. Investors are watching for Pfizer’s Feb. 3 earnings and updates on its 2026 outlook, as the company faces falling COVID demand and looming patent expirations. Trading volume remained moderate, with no major company news released.
26 January 2026
·····
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·······
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
·····
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
······
Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Novavax shares rose nearly 1% in premarket trading Wednesday after Pfizer agreed to license its Matrix-M vaccine adjuvant for up to two infectious disease programs. Pfizer will pay $30 million upfront, with potential milestones and royalties. The deal took effect January 15. Investors are pushing for more details on additional licenses and upfront payments for Q1.
21 January 2026
······
1 2 3 4 … 10

Stock Market Today

Corning stock price hits record close — what’s driving GLW and the next big test

Corning stock price hits record close — what’s driving GLW and the next big test

7 February 2026
Corning shares jumped 8.3% to a record $122.16 Friday, gaining 11% over two sessions amid strong demand for AI infrastructure stocks. The move follows a $6 billion optical fiber deal with Meta and upgraded company forecasts. Shares traded as high as $122.56 and rose 0.6% after hours. COO Avery Nelson sold 1,894 shares for tax withholding, retaining 66,050.
PepsiCo stock: €2.5 billion bond deal lands as investors size up the price-cut gamble

PepsiCo stock: €2.5 billion bond deal lands as investors size up the price-cut gamble

7 February 2026
PepsiCo priced €2.5 billion in euro notes across four maturities, with settlement set for Feb. 11, according to an SEC filing. The company plans to use proceeds for general corporate purposes, including repaying commercial paper. Shares closed at $170.49 Friday, up 1.8%. PepsiCo is also cutting U.S. snack prices by up to 15% after consumer pushback.
Go toTop